Ignite Creation Date:
2024-05-06 @ 3:02 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02187783
Status:
COMPLETED
Last Update Posted:
2019-07-18
First Post:
2014-07-09
Brief Title:
LEE011 for Patients With CDK46 Pathway Activated Tumors SIGNATURE
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors Module 8 - LEE011 for Patients With CDK46 Pathway Activated Tumors
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SIGNATURE
Brief Summary:
The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK46 pathway activated solid tumors andor hematologic malignancies to warrant further study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None